{"id":70368,"date":"2023-02-20T21:47:23","date_gmt":"2023-02-20T21:47:23","guid":{"rendered":"https:\/\/www.imperialcrs.com\/blog\/?p=70368"},"modified":"2023-12-05T17:05:01","modified_gmt":"2023-12-05T17:05:01","slug":"scope-summit-2023-clinical-trials-industry-rejuvenated","status":"publish","type":"post","link":"https:\/\/www.imperialcrs.com\/blog\/patient-recruitment-and-retention\/scope-summit-2023-clinical-trials-industry-rejuvenated\/","title":{"rendered":"SCOPE Summit: Clinical Trials Industry is Rejuvenated and Ready"},"content":{"rendered":"

Imperial\u2019s team attended the annual SCOPE Summit<\/a> in Orlando, where they spoke with hundreds of clinical trials industry colleagues and attended talks and workshops.<\/p>\n

In this post, Imperial team members Dan McDonald, Imogen Cheese, and Ted Corrigan tell us what they found noteworthy at SCOPE.<\/p>\n

The Clinical Trials Industry is Thriving Post-COVID<\/strong><\/h2>\n

Dan McDonald<\/a> told us attendance had clearly increased since last year. \u201cAn obvious indicator was the size and layout of the space needed for the opening night cocktail reception,\u201d he said. \u201cIt was double the size of last year and full. The industry is definitely 100 percent back out there. This includes the sponsor companies, who were the last to lift travel restrictions on their teams. All the major players were there, plus many fledgling companies and newer entries into the market.\u201d<\/p>\n

Diversity<\/h3>\n

Dan said recruitment was again in the spotlight, with diversity as the primary area of focus for the clinical trials industry. \u201cThe need to enroll diverse patient populations has seemed to give patient recruitment firms a new lease on life while also providing an entry point for decentralized trials and other novel companies,\u201d he said. Dan singled out two companies doing important work: Javara<\/a>, which provides clinical research infrastructure and operations for community health networks that support diverse and underserved patient populations, and Emvenio<\/a>, which brings trials to patients via mobile and telehealth technology.<\/p>\n

Hybrid Trial Design<\/h3>\n

Imogen Cheese<\/a> said one of SCOPE\u2019s hot topics was hybrid trial design. \u201cA new type of decentralized trial is evolving,\u201d she said, \u201cand along with it, the importance to fully utilize equipment and resources in a unique way \u2013 taking it to the patients or tailoring it to minimize the patient burden.\u201d<\/p>\n

One of Imogen\u2019s favorite sessions at SCOPE was presented by Caroline Jackson<\/a> of mdgroup, who shared information from a Phase 1 study in a rare disease model. \u201cThe study team had tests and centrifuges taking place in participants\u2019 homes. It was groundbreaking, a true look into the future of trials,\u201d Imogen said. (Dan interviewed Caroline along with Mary Jo Lamberti<\/a> of Tufts Center for the Study of Drug Development and Rick\u00a0O’Hara<\/a> of Endo Pharmaceuticals for his Executive Interview Series; see what they had to say below.)<\/p>\n